Relative risk estimates for Bcl-6+ versus Bcl-6- expression by induction treatment adjusting for IPI and Bcl-2 expression
. | CHOP . | . | . | R-CHOP . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Clinical outcome . | RR . | 95% CI . | P . | RR . | 95% CI . | P . | ||||
| FFS | ||||||||||
| Bcl-6+ | 0.2 | 0.1, 0.4 | < .001 | 1.3 | 0.5, 3.3 | .67 | ||||
| HI/high IPI | 1.7 | 0.8, 3.5 | .17 | 7.1 | 2.3, 2.2 | < .001 | ||||
| Bcl-2+ | 1.0 | 0.5, 2.0 | .91 | 2.3 | 1.1, 4.8 | .03 | ||||
| OS | ||||||||||
| Bcl-6+ | 0.2 | 0.1, 0.3 | < .001 | 2.0 | 0.7, 5.0 | .23 | ||||
| HI/high IPI | 2.4 | 1.0, 5.7 | .05 | 26.0 | 3.2, 208 | .002 | ||||
| Bcl-2+ | 0.7 | 0.3, 1.5 | .36 | 2.2 | 1.0, 4.9 | .06 | ||||
. | CHOP . | . | . | R-CHOP . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Clinical outcome . | RR . | 95% CI . | P . | RR . | 95% CI . | P . | ||||
| FFS | ||||||||||
| Bcl-6+ | 0.2 | 0.1, 0.4 | < .001 | 1.3 | 0.5, 3.3 | .67 | ||||
| HI/high IPI | 1.7 | 0.8, 3.5 | .17 | 7.1 | 2.3, 2.2 | < .001 | ||||
| Bcl-2+ | 1.0 | 0.5, 2.0 | .91 | 2.3 | 1.1, 4.8 | .03 | ||||
| OS | ||||||||||
| Bcl-6+ | 0.2 | 0.1, 0.3 | < .001 | 2.0 | 0.7, 5.0 | .23 | ||||
| HI/high IPI | 2.4 | 1.0, 5.7 | .05 | 26.0 | 3.2, 208 | .002 | ||||
| Bcl-2+ | 0.7 | 0.3, 1.5 | .36 | 2.2 | 1.0, 4.9 | .06 | ||||
Analysis removes the effect of MR to obtain unbiased estimate of induction treatment effect.